Abstract
Importance Data on immune responses following SARS-CoV-2 vaccinations/infections and on detection rate of SARS-CoV-2 infections in anti-CD20 treated patients with multiple sclerosis (pwMS) are important for guiding management of pwMS during the current SARS-CoV-2 pandemic.
Objective To analyze humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections and to determine the detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS.
Design Prospective single-center cohort study from March 2020 to August 2021.
Setting MS referral center, Charité - Universitätsmedizin Berlin, Germany.
Participants 222 consecutive pwMS (128 [57.7%] female, median [range] age 39 [17-81] years). 181 patients were on anti-CD20 therapy at study inclusion, 41 began anti-CD20 therapy during the study. Hospital employees (HE, n=19) served as controls.
Exposures pwMS were exposed to anti-CD20 therapy for 169.5 patient years. 51 patients under anti-CD20 treatment, 14 patients before anti-CD20 treatment, and 19 HE were vaccinated twice against SARS-CoV-2.
Main outcomes SARS-CoV-2 spike protein immunoglobulin (Ig)G (ELISA and immunofluorescence), IgA (ELISA), IgG to four recombinant SARS-CoV-2 antigens (solid phase immunoassay), neutralizing capacity of SARS-CoV-2 antibodies (plaque reduction neutralization test), SARS-CoV-2 IgG avidity (modified ELISA), and SARS- CoV-2 specific T cells (interferon-γ release assay).
Results Following two SARS-CoV-2 vaccinations, median (IQR) levels of SARS-CoV-2 spike protein IgG (OD ratio: 1.2 [0.1-5.1] vs. 9.0 [6.8-9.9] vs. 8.8 [8.0-9.4], p<0.0001), neutralizing capacity (PRNT50 Titer: 40 [0-80] vs. 640 [80-640] vs. 640 [320-640], p≤0.006), and antibody avidity (43.6% [14.8-54.6%] vs. 84.1% [53.1-86.8%] vs. 89.7 [76.8-93.4%], p≤0.003) were lower in anti-CD20 treated pwMS than in pwMS before initiation of anti-CD20 therapy and in HE. All anti-CD20 treated pwMS vaccinated twice developed SARS-CoV-2 specific T cells, whose levels did not differ from those of pwMS before initiation of anti-CD20 therapy and HE. SARS-CoV-2 IgG levels (r=0.42, p=0.002) and antibody avidity (r=0.70, p<0.001) increased with time between anti-CD20 infusion and second vaccination. The detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS (2.36/100 patient years) was similar to that of RT-PCR confirmed SARS-CoV-2 cases in the general Berlin population (3.75/100 person years) during the study period.
Interpretation These findings are relevant for treatment decisions as well as management of SARS-CoV-2 vaccinations in pwMS.
Question Do anti-CD20 treated patients with multiple sclerosis (pwMS) develop humoral and cellular immune responses after SARS-CoV-2 vaccination/infection?
Findings In a prospective cohort study, levels, avidity and neutralizing capacity of SARS-CoV-2 specific antibodies were diminished, but SARS-CoV-2 specific T cell responses preserved in pwMS following SARS-CoV-2 vaccination/infection. SARS-CoV-2 antibody levels and functionality increased with increasing time from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination.
Meaning A robust T cell response following vaccinations/infections may contribute to protection against COVID-19 in anti-CD20 treated pwMS. Time between anti-CD20 therapy and vaccination might be key for sufficient SARS-CoV-2 specific humoral immune responses.
Competing Interest Statement
Parts of this work were supported by grants from the Berlin Institute of Health (BIH) and Berlin University Alliance to CD and VMC. This study was further supported by the German Ministry of Education and Research through Forschungsnetzwerk der Universitaetsmedizin zu COVID-19, COVIM, FKZ: 01KX2021 to CD and VMC, and projects VARIPath (01KI2021) to VMC. VMC is a participant in the BIH-Charite Clinician Scientist Program funded by Charite - Universitaetsmedizin Berlin and the Berlin Institute of Health. KR is a participant in the BIH Clinical Fellow Program funded by Stiftung Charite. FP is a participant in the BIH-Charite Clinician Scientist Program funded by Charite - Universitaetsmedizin Berlin and the Berlin Institute of Health.
Funding Statement
Parts of this work were supported by grants from the Berlin Institute of Health (BIH) and Berlin University Alliance to CD and VMC. This study was further supported by the German Ministry of Education and Research through Forschungsnetzwerk der Universitaetsmedizin zu COVID-19, COVIM, FKZ: 01KX2021 to CD and VMC, and projects VARIPath (01KI2021) to VMC. VMC is a participant in the BIH-Charite Clinician Scientist Program funded by Charite - Universitaetsmedizin Berlin and the Berlin Institute of Health. KR is a participant in the BIH Clinical Fellow Program funded by Stiftung Charite. FP is a participant in the BIH-Charite Clinician Scientist Program funded by Charite- Universitaetsmedizin Berlin and the Berlin Institute of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethical committee of Charite - Universitaetsmedizin Berlin (EA2/152/21 and EA1/068/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# these authors jointly supervised this work
Data Availability
All data produced in the present study are contained in the manuscrip or are available upon reasonable request to the authors.
